In Stock, Ready to Ship!
$80.00 — or subscribe and save 20%
99% Pure | USA Made | Multi DoseSnap-8, also known as Acetyl Octapeptide-3, is a next-generation cosmetic research peptide often referred to as a topical Botox alternative in laboratory settings. It is an octapeptide derivative of the well-known Argireline® (Acetyl Hexapeptide-8), designed for enhanced efficacy in reducing the depth of facial expression lines and wrinkles in research models. Unlike neurotoxins, Snap-8 operates by targeting the SNARE complex — a key mechanism in neurotransmitter release — thereby inhibiting facial muscle contractions without paralytic effects. Its topical research application focuses on wrinkle formation, dynamic muscle tension, and the aging process at the neuromuscular junction level. At Real Peptides, our Snap-8 peptide is ≥99% pure, U.S.-made, and third-party tested for research integrity.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
Snap-8 (Acetyl Octapeptide-3) is an advanced cosmetic peptide composed of eight amino acids. It is engineered to modulate the SNARE protein complex that governs muscle contraction and neurotransmitter release, making it a targeted research tool in wrinkle reduction and facial muscle relaxation. Snap-8 expands upon the Argireline® model (Acetyl Hexapeptide-8) with enhanced functionality and broader efficacy in dynamic wrinkle areas.
Researchers select Snap-8 to explore non-invasive neuromuscular relaxation mechanisms relevant to facial aesthetics. Unlike neurotoxins like Botox® that require injection and act irreversibly, Snap-8 provides a reversible and topical research pathway. It has been shown in vitro and in clinical trials to reduce expression wrinkle depth by up to 63% in as little as 28 days of treatment in research models.
Additionally, its compatibility with topical serums, patches, and creams makes it ideal for transdermal delivery studies, expanding its application across diverse cosmetic testing fields.
Don't hestitate to contact us
End of Content.
